Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b Targeted off-the-shelf treatment provides much-needed new option for people with relapsed or refractory diffuse large B-cell lymphoma Polivy approval is based on a phase Ib/II study, the firs

Roche today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS).

Greatest improvement in invasive disease-free survival (iDFS) remains in patients at high risk of recurrence, such as those with lymph node-positive disease with a 28% reduction in the risk of recurrence or death, corresponding to an absolute iDFS benefit of 4.5% at six years With longer f

In an updated analysis of the CLL14 study, Venclexta/Venclyxto plus Gazyva/Gazyvaro achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukaemia At four-year follow-up of the MURANO study, Venclexta/Venclyxto plus MabThera/Rituxan continued t

All antitrust approvals required to close the transaction received. Roche and Spark Therapeutics, Inc.

Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment Phase III FeDeriCa study showed non-inferior pharmacokinetics and comparable efficacy and safety with the fixed-dose combina

Accu-Chek SugarView is the first app that determines blood glucose ranges by taking photos with the smartphone camera without the need of a blood glucose meter. It is designed to help non-insulin-dependent people with type 2 diabetes or pre-diabetes live healthier lives in-between doctors' visits.

Approval based on the Phase III IMpower130 study showing the Tecentriq plus chemotherapy combination demonstrated a significant overall survival and progression-free survival benefit Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) in combinat